Sep 8, 2026 · 58 min
ECT offers powerful treatment while leaving hard questions unanswered
Ep 221 Electroconvulsive Therapy Part 2: A current conversation
Modern ECT can rapidly help severe illness, but memory risks, limited access, stigma, and uncertain mechanisms complicate its use.
- 1Modern ECT combines anesthesia, physiological monitoring, carefully placed electrodes, and repeated treatments tailored to seizure thresholds.
- 2ECT has strong evidence for treatment-resistant depression and can also help catatonia, bipolar disorder, schizophrenia, and anti-NMDA receptor encephalitis.
- 3Memory loss, informed consent, uneven access, and persistent stigma shape decisions about a treatment whose biology remains incompletely understood.
Don't miss
Dr. Leonardo Lopez’s account of treating a five-year-old with anti-NMDA receptor encephalitis illustrates ECT’s use beyond depression.
The brief
Modern ECT is a monitored medical procedure, not the uncontrolled spectacle depicted in films: anesthesia, oxygen, EEG, EMG, and precise electrode placement structure each session.
The treatment’s strongest evidence is in treatment-resistant depression, but clinicians also use it for catatonia, bipolar disorder, schizophrenia, and anti-NMDA receptor encephalitis.
ECT can bring rapid benefit, yet memory loss remains the central risk–benefit question, with uncertainty about permanence and differences between bilateral and unilateral treatment.
Dr. Leonardo Lopez describes ECT as routine and high-volume in specialized hospitals, while identifying qualified providers and treatment capacity as its largest practical barriers.
The episode’s child case of anti-NMDA receptor encephalitis shows why ECT’s applications extend beyond depression, even as its biological mechanism remains unsettled.
Featuring
Brain on Fire
One Flew Over the Cuckoo's Nest
Advances in Care
Weill Cornell MedicineBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.